Dark Matter Bio
A venture-built thesis at the edge of bioscience, data, and longevity.
Four converging forces creating unprecedented opportunity
Breakthroughs in genomics, epigenetics, proteomics, and other biosciences are enabling new ways to understand and treat disease.
Newly discovered biomarkers, combined with real-time data collection, give us continuous, measurable signals about biological age, risk, and response.
Consumers and institutions are demanding personalized, data-driven, future-forward health innovations, not one-size-fits-all care.
Repeat founders from software and infrastructure now want to apply their company-building craft to breakthroughs in health and longevity.
What sets us apart in the longevity investment landscape
Trusted networks at the intersection of Silicon Valley, bioscience research, inventors, and company builders.
Investing partners with a track record several standard deviations above venture in general, including biotech and health.
Deep domain experience paired with the entrepreneurial energy of a modern venture firm.
Geekery, alignment, and wide, deep relationships across the ecosystem give Dark Matter the right to win the most interesting opportunities.
Investing at the edge of what's knowable.
fund@darkmatter.bio